Skip to content

Remimazolam with propofol is moderately sedated in painless gastrointestinal endoscopy in obese patients apply effects

Remimazolam with propofol is moderately sedated in painless gastrointestinal endoscopy in obese patients apply effects

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096953
Enrollment
Unknown
Registered
2025-02-10
Start date
2025-02-17
Completion date
Unknown
Last updated
2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless gastrointestinal endoscopy anesthesia

Interventions

Rimazzolam group (group R):Sufentanil (0.1ug/kg) was injected intravenously, and Rimazzolam was given 1mg/ time after 3 minutes, with intermittent intravenous injection (following the principle of ind
Propofol group (group P):Intravenous sufentanil (0.1ug/kg), propofol 10 mg/ time after 3 minutes, and intermittent intravenous injection (following the principle of individualization) until the preset

Sponsors

People's Hospital of Ningxia Hui Autonomous Region
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Outpatients who undergo painless gastrointestinal endoscopy in the Digestive Endoscopy Center; (2) Age 18~60 years old, gender is not limited; (3) BMI28~40 kg/m^2;(4) ASA grade I and II; (5) Have normal cognitive and communication skills; (6) Voluntarily sign to be informed.

Exclusion criteria

Exclusion criteria: (1) Severe respiratory, circulatory or endocrine diseases (severe hypertension, unstable angina pectoris, asthma attack, etc.); (2) Coagulation dysfunction; (3) With abnormal functions of important organs such as heart, lung, liver and kidney; (4) Contraindications for the use of propofol, ramizolam and other narcotic drugs; (5) Long-term use of sedative and analgesic drugs; (6) Acute upper gastrointestinal bleeding or gastrointestinal perforation; (7) Have a history of respiratory tract infection in recent 2 weeks; (8) Psychosocial diseases or cognitive dysfunction.

Design outcomes

Primary

MeasureTime frame
Incidence of intraoperative hypoxemia (< 90%) and severe hypoxemia (< 85%).;

Secondary

MeasureTime frame
Success rate of entering the mirror;SpO2 at different time points;The patient's performance when the first entry was successful and the reasons why the patient failed in the first entry.;The evaluation of sedation effect, anesthesia induction time, gastroscopy time, anesthesia recovery time, hospital leave time and sedative dosage were recorded.;Patient comfort, patient satisfaction and physician satisfaction scores within 24 hours after gastroscopy.;Adverse reactions during and after gastroscopy, postoperative memory of the examination process and postoperative delirium 72 hours later.;Mean arterial pressure at different time points;Heart rate at different time points;

Countries

China

Contacts

Public ContactWang Yun

People's Hospital of Ningxia Hui Autonomous Region

Wangyun10483@126.com+86 189 9510 5832

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026